Cargando…

4119 Cholecystokinin (CCK) Receptor Antagonist Reverses Nonalcoholic Steatohepatitis (NASH) by Reducing Hepatic Macrophages and Inflammatory Cytokines

OBJECTIVES/GOALS: NASH increases the risk of cirrhosis and liver cancer. High-fat diets increase CCK levels and CCK receptors have been identified on fibroblasts and immune cells. We hypothesized that CCK receptor blockade could prevent NASH by altering the hepatic microenvironment and macrophage ac...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gay, Martha, Safronenka, Anita, Cao, Hong, Tucker, Robin, Shivapurkar, Narayan, Kruger, Annie, Smith, Jill
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cambridge University Press 2020
Materias:	Mechanistic Basic to Clinical
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8823289/ http://dx.doi.org/10.1017/cts.2020.293

Ejemplares similares

A Cholecystokinin Receptor Antagonist Halts Nonalcoholic Steatohepatitis and Prevents Hepatocellular Carcinoma
por: Tucker, Robin D., et al.
Publicado: (2019)

4121 The beneficial, anti-fibrotic effects of chemokine receptor 2 and 5 antagonists on fat-exposed mouse primary hepatic stellate cells (pHSCs)
por: Kruger, Annie J., et al.
Publicado: (2020)

25380 Cholecystokinin-B Receptor -Mediates Growth of Hepatocellular Carcinoma
por: Gay, Martha Dee, et al.
Publicado: (2021)

2297: Dietary fat stimulates growth of pancreatic cancer growth through the cholecystokinin receptor
por: Nadella, Sandeep, et al.
Publicado: (2018)

Cholecystokinin Receptor Antagonist Improves Efficacy of Chemotherapy in Murine Models of Pancreatic Cancer by Altering the Tumor Microenvironment
por: Malchiodi, Zoe X., et al.
Publicado: (2021)

Safety and Dosing Study of a Cholecystokinin Receptor Antagonist in Non‐alcoholic Steatohepatitis
por: Rabiee, Atoosa, et al.
Publicado: (2022)

Proglumide Reverses Nonalcoholic Steatohepatitis by Interaction with the Farnesoid X Receptor and Altering the Microbiome
por: Gay, Martha D., et al.
Publicado: (2022)

Treatment with a Cholecystokinin Receptor Antagonist, Proglumide, Improves Efficacy of Immune Checkpoint Antibodies in Hepatocellular Carcinoma
por: Shivapurkar, Narayan, et al.
Publicado: (2023)

Cholecystokinin (CCK) and its receptors (CCK1R and CCK2R) in chickens: functional analysis and tissue expression
por: Wan, Yiping, et al.
Publicado: (2022)

Cholecystokinin Revisited: CCK and the Hunger Trap in Anorexia Nervosa
por: Cuntz, Ulrich, et al.
Publicado: (2013)

The burden of nonalcoholic steatohepatitis (NASH) in the United States
por: Tapper, Elliot B., et al.
Publicado: (2023)

Cholecystokinin Receptor Antagonist Induces Pancreatic Stellate Cell Plasticity Rendering the Tumor Microenvironment Less Oncogenic
por: Jolly, Gurbani, et al.
Publicado: (2023)

Neural circuit mechanisms of the cholecystokinin (CCK) neuropeptide system in addiction
por: Ma, Yihe, et al.
Publicado: (2022)

Nonalcoholic steatohepatitis (NASH) is associated with cardiac remodeling and dysfunction
por: Simon, Tracey G., et al.
Publicado: (2017)

Exosomal microRNAs and Progression of Nonalcoholic Steatohepatitis (NASH)
por: Qi, Xiaoyan, et al.
Publicado: (2022)

Assessment of cholecystokinin 2 receptor (CCK2R) in neoplastic tissue
por: Roy, Jyoti, et al.
Publicado: (2016)

A Novel Animal Model of Nonalcoholic Steatohepatitis (NASH): Hypoxemia Enhances the Development of NASH
por: Takayama, Fusako, et al.
Publicado: (2009)

4369 Reprogramming of vascular smooth muscle cells to multipotent progenitor cells contributes to progression of atherosclerosis
por: Dubner, Allison Milfred, et al.
Publicado: (2020)

Molecular Pathogenesis of Nonalcoholic Steatohepatitis- (NASH-) Related Hepatocellular Carcinoma
por: Kutlu, Ozlem, et al.
Publicado: (2018)

A new method to induce nonalcoholic steatohepatitis (NASH) in mice
por: Savari, Feryal, et al.
Publicado: (2019)

38766 Massively Parallel Reporter Assay Reveals Functional Impact of 3™-UTR SNPs Associated with Neurological and Psychiatric Disorders
por: Chen, Andy B., et al.
Publicado: (2021)

Current Status in Testing for Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH)
por: Drescher, Hannah K., et al.
Publicado: (2019)

Effects of Cholecystokinin (CCK) on Gut Motility in the Stomachless Fish Ballan Wrasse (Labrus bergylta)
por: Le, Hoang T. M. D., et al.
Publicado: (2019)

Selective Activation of Cholecystokinin-Expressing GABA (CCK-GABA) Neurons Enhances Memory and Cognition
por: Whissell, Paul D., et al.
Publicado: (2019)

Plasma Pentraxin3 is a Novel Marker for Nonalcoholic Steatohepatitis (NASH)
por: Yoneda, Masato, et al.
Publicado: (2008)

Population Pharmacokinetics of Morphine in Patients With Nonalcoholic Steatohepatitis (NASH) and Healthy Adults
por: Pierre, V, et al.
Publicado: (2017)

Imaging Fibrogenesis in a Diet-Induced Model of Nonalcoholic Steatohepatitis (NASH)
por: Hartimath, S. V., et al.
Publicado: (2019)

Hepatic Molecular Signatures Highlight the Sexual Dimorphism of Nonalcoholic Steatohepatitis (NASH)
por: Vandel, Jimmy, et al.
Publicado: (2020)

The methyltransferase METTL3 negatively regulates nonalcoholic steatohepatitis (NASH) progression
por: Li, Xinzhi, et al.
Publicado: (2021)

Cholecystokinin Receptor-Targeted Polyplex Nanoparticle Inhibits Growth and Metastasis of Pancreatic Cancer
por: Burks, Julian, et al.
Publicado: (2018)

Plasminogen activator inhibitor (PAI)-1 suppresses inhibition of gastric emptying by cholecystokinin (CCK) in mice()
por: Gamble, Joanne, et al.
Publicado: (2013)

Plasma levels of vitamin E and carotenoids are decreased in patients with nonalcoholic steatohepatitis (NASH)
por: Erhardt, A, et al.
Publicado: (2011)

A structured literature review of interventions used in the management of nonalcoholic steatohepatitis (NASH)
por: Povsic, Manca, et al.
Publicado: (2019)

Targeting of Secretory Proteins as a Therapeutic Strategy for Treatment of Nonalcoholic Steatohepatitis (NASH)
por: Kim, Kyeongjin, et al.
Publicado: (2020)

Endoscopic duodenal mucosal resurfacing for nonalcoholic steatohepatitis (NASH): a pilot study
por: Hadefi, Alia, et al.
Publicado: (2021)

The Beneficial Effects of Triterpenic Acid and Acteoside in an In Vitro Model of Nonalcoholic Steatohepatitis (NASH)
por: Salvoza, Noel, et al.
Publicado: (2022)

The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review
por: Younossi, Zobair M., et al.
Publicado: (2023)

2529: Clinical determinants of clopidogrel responsiveness in a heterogeneous cohort of Caribbean Hispanics
por: Suarez, Dagmar Fredy Hernandez, et al.
Publicado: (2018)

2519: A quantitative disintegration method to evaluate polymeric films
por: Grab, Sheila, et al.
Publicado: (2018)

2370: Understanding epicardial fat biology by imaging
por: Stojanovska, Jadranka, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_655jo884fg0ead938039a0nqos